A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Amneal Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 300 shares of AMRX stock, worth $1,905. This represents 0.0% of its overall portfolio holdings.

Number of Shares
300
Previous 6,600 95.45%
Holding current value
$1,905
Previous $40,000 97.5%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$5.24 - $6.34 $7.49 Million - $9.06 Million
-1,429,607 Reduced 22.0%
5,067,483 $30.7 Million
Q4 2023

Feb 14, 2024

BUY
$3.36 - $6.21 $12.8 Million - $23.6 Million
3,808,360 Added 141.64%
6,497,090 $39.4 Million
Q3 2023

Nov 14, 2023

BUY
$2.76 - $4.59 $4.12 Million - $6.85 Million
1,493,222 Added 124.9%
2,688,730 $11.3 Million
Q2 2023

Aug 14, 2023

BUY
$1.33 - $3.1 $213,205 - $496,945
160,305 Added 15.49%
1,195,508 $3.71 Million
Q1 2023

May 15, 2023

BUY
$1.27 - $2.7 $438,720 - $932,712
345,449 Added 50.08%
1,035,203 $1.44 Million
Q4 2022

Feb 14, 2023

SELL
$1.96 - $2.61 $1.88 Million - $2.5 Million
-956,839 Reduced 58.11%
689,754 $1.37 Million
Q3 2022

Nov 14, 2022

BUY
$2.02 - $3.62 $429,660 - $769,984
212,703 Added 14.83%
1,646,593 $3.33 Million
Q2 2022

Aug 15, 2022

SELL
$3.01 - $4.46 $94,002 - $139,285
-31,230 Reduced 2.13%
1,433,890 $4.56 Million
Q1 2022

May 16, 2022

SELL
$3.9 - $4.89 $510,225 - $639,744
-130,827 Reduced 8.2%
1,465,120 $6.11 Million
Q4 2021

Feb 14, 2022

BUY
$3.95 - $5.85 $1.72 Million - $2.54 Million
435,040 Added 37.47%
1,595,947 $7.64 Million
Q3 2021

Nov 15, 2021

BUY
$4.31 - $5.64 $2.31 Million - $3.02 Million
534,969 Added 85.47%
1,160,907 $6.2 Million
Q2 2021

Aug 16, 2021

BUY
$5.12 - $6.82 $27,765 - $36,984
5,423 Added 0.87%
625,938 $3.2 Million
Q1 2021

May 17, 2021

SELL
$4.74 - $7.38 $4.07 Million - $6.34 Million
-859,409 Reduced 58.07%
620,515 $4.18 Million
Q4 2020

Feb 16, 2021

BUY
$3.95 - $5.42 $681,758 - $935,475
172,597 Added 13.2%
1,479,924 $6.76 Million
Q3 2020

Nov 16, 2020

BUY
$3.54 - $5.27 $2.54 Million - $3.78 Million
717,014 Added 121.46%
1,307,327 $5.07 Million
Q2 2020

Aug 14, 2020

BUY
$2.87 - $5.46 $685,175 - $1.3 Million
238,737 Added 67.9%
590,313 $2.81 Million
Q1 2020

May 15, 2020

SELL
$2.46 - $5.35 $215,825 - $469,376
-87,734 Reduced 19.97%
351,576 $1.22 Million
Q4 2019

Feb 14, 2020

SELL
$2.65 - $5.56 $559,004 - $1.17 Million
-210,945 Reduced 32.44%
439,310 $2.12 Million
Q3 2019

Nov 14, 2019

BUY
$2.29 - $7.1 $169,240 - $524,718
73,904 Added 12.82%
650,255 $1.89 Million
Q2 2019

Aug 14, 2019

SELL
$6.44 - $14.29 $182,142 - $404,164
-28,283 Reduced 4.68%
576,351 $4.13 Million
Q2 2018

Aug 10, 2018

BUY
$13.95 - $20.2 $8.43 Million - $12.2 Million
604,634 New
604,634 $0

Others Institutions Holding AMRX

About Amneal Pharmaceuticals, Inc.


  • Ticker AMRX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 151,408,992
  • Market Cap $961M
  • Description
  • Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and comme...
More about AMRX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.